Sort   by:  
 Page size 
ProteomicsActivity of the novel BTK inhibitor TG-1701 is associated with the disruption of the Ikaros signaling pathway in responder B-NHL patients and with sensitization to anti-CD20 therapy in B-NHL xenografts
Covalent Bruton's tyrosine kinase inhibitors (BTKis) have transformed the treatment of B-cell non-Hodgkin lymphoma (B-NHL), including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), but their activity has been limited by off-target toxicity and acquired drug resistance. TG-1701 is...
ORGANISM(S): Homo sapiens (Human) 
2021-09-22 | PXD023231 | Pride
Xenografts Tmt B-nhl Btk Maxquant Tg-1701 Phosphoproteomics Ikaros 
UnknownAntitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.
Not available
S-EPMC9401565 | biostudies-literature
UnknownNovel model predicts diastolic cardiac dysfunction in type 2 diabetes.
Not available
S-EPMC10798288 | biostudies-literature
Sort   by:  
 Page size